Established IGF-1 LR3 stacks
Anabolic Recovery Research
Goal: Combined anabolic signaling and tissue repair
Preclinical work has combined IGF-1 LR3 with BPC-157 to model the interaction between IGF-1 receptor-driven growth signals and BPC-157's angiogenic and gut-protective actions in recovery contexts.
GH Axis Completion
Goal: Upstream GH stimulation with direct IGF-1 supplementation
Some researchers pair GH secretagogues (which raise IGF-1 indirectly) with exogenous IGF-1 LR3 to study both arms of the GH/IGF-1 axis simultaneously.
How to think about stacking
- Mechanism diversity beats redundancy. Pairing compounds that hit different pathways usually outperforms stacking two compounds with similar mechanisms.
- Track one variable at a time. Starting two peptides simultaneously makes it impossible to attribute effects. Research protocols typically introduce stacks sequentially.
- Side-effect interactions. Some peptides compound each other's side effects (e.g., GLP-1 agonists with other GI-active compounds). Review side-effect profiles before stacking.